GlassScriptPhysician profile
Jenny Littrell
NPI 1013316025
$6,256.83
in general payments reported to CMS, 2019-2025
57 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,195 · 2022: $1,438 · 2023: $923 · 2024: $1,334 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,566 · Education: $58.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,565.78 |
| Education | $58.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $656.98 | 2021-2025 | Reblozyl |
| Janssen Biotech, INC. | $544.43 | 2021-2025 | Darzalex, Rybrevant, Tecvayli |
| Abbvie INC. | $420.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $381.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $344.20 | 2021-2025 | Enhertu, Bevespi Aerosphere, Lynparza |
| Pfizer INC. | $336.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $280.17 | 2021-2025 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $271.41 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $232.02 | 2021-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $187.65 | 2021-2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $168.76 | 2021-2023 | Kyprolis, Lumakras, Blincyto |
| Daiichi Sankyo INC. | $144.62 | 2023-2025 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $136.05 | 2021-2023 | Xpovio |
| Glaxosmithkline, LLC. | $128.80 | 2021-2025 | Jemperli, Ojjaara, Shingrix |
| Gilead Sciences, INC. | $126.08 | 2021-2023 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $125.43 | 2022-2025 | Alunbrig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $120.03 | 2021-2025 | |
| Genentech USA, INC. | $96.67 | 2022-2023 | Venclexta, Alecensa, Tecentriq |
| Incyte Corporation | $92.67 | 2021-2025 | Pemazyre, Monjuvi, Jakafi |
| Ipsen Biopharmaceuticals, INC | $87.98 | 2021-2025 | Onivyde |
| Eisai INC. | $85.45 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $82.95 | 2024-2025 | Libtayo |
| Myovant Sciences INC. | $81.19 | 2021-2022 | |
| Genzyme Corporation | $66.96 | 2021-2023 | |
| Mirati Therapeutics, INC. | $61.43 | 2023-2024 | Krazati |
| Lilly USA, LLC | $58.31 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.44 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $50.08 | 2021-2025 | |
| Springworks Therapeutics, INC. | $46.69 | 2024-2025 | Ogsiveo |
| Seagen INC. | $46.59 | 2021-2023 | Padcev |
| Pharmacosmos Therapeutics INC. | $46.57 | 2023 | Monoferric |
| Beone Medicines USA, INC. | $41.83 | 2025 | Tevimbra, Brukinsa |
| Glaukos Corporation | $41.00 | 2025 | Idosetr, Istent Infinite, Iaccess Precision Blade |
| G1 Therapeutics, INC. | $36.86 | 2022 | |
| Sun Pharmaceutical Industries INC. | $36.29 | 2021-2023 | Yonsa, Odomzo |
| Adc Therapeutics America, INC. | $35.46 | 2022-2024 | |
| Abiomed | $35.00 | 2024 | Impella |
| Adaptive Biotechnologies Corporation | $34.96 | 2025 | Clonoseq |
| Epizyme, INC. | $31.92 | 2021 | |
| Alexion Pharmaceuticals, INC. | $29.25 | 2022-2024 | Ultomiris |
| Astellas Pharma US INC | $28.22 | 2024 | |
| Genmab U.S., INC. | $27.99 | 2024 | Tivdak |
| Tersera Therapeutics LLC | $27.20 | 2025 | Zoladex |
| Array Biopharma INC | $27.16 | 2024 | Tukysa, Braftovi, Mektovi |
| Legend Biotech USA INC. | $24.59 | 2025 | Carvykti |
| Sobi, INC | $23.79 | 2023 | |
| Organon LLC | $23.59 | 2021 | |
| Blueprint Medicines Corporation | $23.52 | 2024 | Ayvakit |
| Emd Serono, INC. | $21.33 | 2025 | |
| Iovance Biotherapeutics, INC. | $21.12 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $20.64 | 2025 | Orserdu |
| Nestle Healthcare Nutrition INC. | $18.86 | 2021 | |
| Mylan Institutional INC. | $17.61 | 2021 | |
| Morphosys, US INC. | $16.04 | 2022 | |
| Kite Pharma, INC. | $15.85 | 2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $15.47 | 2021 | |
| Eusa Pharma (US) LLC | $15.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Littrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.